The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
There is no confirmed drug therapy for RP-ILD. Prognosis is poor of regular treatment. The
study is designed to compare efficacy and safety of tocilizumab versus regular treatment in
participants with severe RP-ILD secondary to systemic diseases.